Merck has an experimental COVID-19 pill, Molnupiravir, which utilizes a novel approach against the virus. An early study with a small sample reports that it may have an acceptable safety profile. However, the experts at the FDA share a few concerns about some of the side effects; it carries a risk of birth defects in unborn children, and the ability of the drug to change the coronavirus’ signature spike protein which allows it to enter human cells and increases the risk of new variants emerging as a result. Those major safety concerns are prompting the FDA to seek other experts’ advice on the safety and effectiveness on it before granting approval.
Read the full article here